Abbott Laboratories (NYSE:ABT) Gets FDA Drug Approval

XCSFDHG46767FHJHJF

tdp2664 E money daily The FDA has approved two new longer acting Lupron drugs made by Abbott Laboratories (NYSE:ABT). Abbott Laboratories (NYSE:ABT) Gets FDA Drug Approval According to an announcement made by the leading health care company Abbott Laboratories (NYSE:ABT), the US Food and Drug Administration (FDA) has approved its two longer-acting doses of its drug Lupron. Abbott Laboratories (NYSE:ABT) said in a statement, "The FDA approved two doses of Lupron that last for three months each, allowing patients to be injected with the drug four times a year instead of once every month." Abbott Laboratories (NYSE:ABT) shares were at 48.87 at the end of the last day’s trading. There’s been a -8.5% change in the stock price over the past 3 months. Abbott Laboratories (NYSE:ABT) Analyst Advice Consensus Opinion: Hold Mean recommendation: 2.02 (1=Strong Buy, 5=Strong Sell) 3 Months Ago: 1.98 Zack’s Rank: 2 out of 14 in the industry